Kyle Rose

Stock Analyst at Canaccord Genuity

(2.67)
# 2,176
Out of 5,076 analysts
114
Total ratings
53.26%
Success rate
13.81%
Average return

Stocks Rated by Kyle Rose

Smith & Nephew
Feb 26, 2025
Maintains: Hold
Price Target: $27
Current: $32.72
Upside: -17.48%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $304$324
Current: $310.83
Upside: +4.24%
Stryker
Jan 29, 2025
Maintains: Buy
Price Target: $420$435
Current: $372.32
Upside: +16.83%
Globus Medical
Dec 20, 2023
Maintains: Buy
Price Target: $67$71
Current: $89.79
Upside: -20.93%
Enovis
Dec 20, 2023
Maintains: Buy
Price Target: $65$71
Current: $29.36
Upside: +141.83%
InMode
Oct 13, 2023
Downgrades: Hold
Price Target: $55$22
Current: $14.30
Upside: +53.85%
The Beauty Health Company
Aug 25, 2023
Assumes: Buy
Price Target: $10
Current: $1.49
Upside: +571.14%
Alphatec Holdings
Aug 4, 2023
Maintains: Buy
Price Target: $17$22
Current: $21.96
Upside: +0.18%
DexCom
Jul 28, 2023
Maintains: Buy
Price Target: $135$150
Current: $63.52
Upside: +136.15%
Vicarious Surgical
May 31, 2023
Maintains: Buy
Price Target: $360$270
Current: $2.66
Upside: +10,050.38%
Maintains: Buy
Price Target: $24$27
Current: $18.87
Upside: +43.08%
Reiterates: Buy
Price Target: $15
Current: $1.13
Upside: +1,227.43%
Reiterates: Buy
Price Target: $15
Current: $28.53
Upside: -47.42%
Maintains: Market Perform
Price Target: $125$122
Current: $156.94
Upside: -22.26%
Upgrades: Buy
Price Target: $3$4
Current: $5.82
Upside: -31.27%
Downgrades: Hold
Price Target: n/a
Current: $7.61
Upside: -
Downgrades: Hold
Price Target: $165$125
Current: $94.76
Upside: +31.91%